New pill aims to quiet Schizophrenia's worst symptoms
NCT ID NCT07038876
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times
Summary
This study tests an experimental oral medication, ML-007C-MA, in 307 adults hospitalized with schizophrenia who are having a sudden worsening of psychosis. The goal is to see if the drug reduces symptoms like hallucinations and delusions better than a placebo. Participants take the drug or placebo daily while staying in the hospital, and doctors measure changes using standard symptom scales.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinical Site
Little Rock, Arkansas, 72211, United States
-
Clinical Site
Bellflower, California, 90706, United States
-
Clinical Site
Culver City, California, 90230, United States
-
Clinical Site
Garden Grove, California, 92845, United States
-
Clinical Site
Lemon Grove, California, 91945, United States
-
Clinical Site
Los Angeles, California, 90015, United States
-
Clinical Site
Montclair, California, 91763, United States
-
Clinical Site
Orange, California, 92868, United States
-
Clinical Site
Riverside, California, 92506, United States
-
Clinical Site
San Diego, California, 92123, United States
-
Clinical Site
Sherman Oaks, California, 91403, United States
-
Clinical Site
Torrance, California, 90504, United States
-
Clinical Site
Hollywood, Florida, 33024, United States
-
Clinical Site
Miami Lakes, Florida, 33016, United States
-
Clinical Site
West Palm Beach, Florida, 33407, United States
-
Clinical Site
Atlanta, Georgia, 30331, United States
-
Clinical Site
Decatur, Georgia, 30030, United States
-
Clinical Site
Chicago, Illinois, 60640, United States
-
Clinical Site
Marlton, New Jersey, 08053, United States
-
Clinical Site
Staten Island, New York, 10314, United States
-
Clinical Site
North Canton, Ohio, 44720, United States
-
Clinical Site
Austin, Texas, 78754, United States
-
Clinical Site
DeSoto, Texas, 75115, United States
-
Clinical Site
Richardson, Texas, 75080, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new pill for schizophrenia pass its first human test?
- Can a new daily pill offer safer Long-Term control of schizophrenia?
- Can an Anti-Seizure drug quiet the brain and sharpen thinking in schizophrenia?
- Can a dissolving film tame agitation in schizophrenia?
- Can a phone app teach the brain to read social cues?
- Can a gentle brain current silence voices that medication Can't?